CEO Pascal Soriot indicates AstraZeneca (NYSE:AZN) may be looking to make a third strategic deal...

CEO Pascal Soriot indicates AstraZeneca (NYSE:AZN) may be looking to make a third strategic deal similar to previous arrangements with Bristol-Myers Squibb and Amgen under which the company will, in FT's words, "share the costs and benefits of experimental drug development." Despite a few recent slips regarding trial results for Onglyza and "slow uptake" for Brilique, Soriot says the "pipeline is growing … rapidly." You "can't develop everything," he notes, adding that "partnering with other companies … leverages capabilities."